Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that formulary and reimbursement committees will continue to restrict the majority of high-priced drugs for the treatment of skin and soft tissue infections to second- or third-line use because of the availability of equally efficacious generic drugs that can be first-line options.

"Most emerging therapies are effective against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE)," said Jason LaBonte, analyst at Decision Resources. "However, these premium-priced products will be held in reserve behind the less expensive drug vancomycin, though Pfizer's Zyvox will continue to gain market share thanks to its oral formulation."

The new Pharmacor study entitled Skin and Soft Tissue Infections also finds that Wyeth's tigecycline will be a popular choice for the polymicrobial infections that dominate diabetic ulcers as well as a good empiric drug choice for patients that may be at risk for MRSA infection.

No Clear Definition for Skin and Soft Tissue Infections Exists

Experts say that no consensus definition for skin and soft tissue infections (SSTIs) exists. Rather, they believe that SSTI is an umbrella category that comprises several individual diagnoses, including cellulitis, abscesses, gangrene, necrotizing fasciitis, mastitis, and infected diabetic ulcers. Experts believe that a complicated infection is most clearly identified by its need for hospitalization, whereas uncomplicated SSTIs are treated in the community by primary care physicians.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

Endocrinologists and Primary Care Physicians Have Different Rationales Driving Their Choice of Antidiabetic Drugs

View Now